Crossmark

Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy

Crossref DOI link: https://doi.org/10.1186/s12916-024-03462-4

Published Online: 2024-06-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shan, Jianzhen http://orcid.org/0000-0001-5308-7056
Liu, Zhen

Chen, Songan

Du, Chengli

Li, Bing

Ruan, Lingxiang

Kong, Mei

Wang, Lingjie

Du, Miaoyan

Shi, Shuo

Qiao, Guoliang

Tian, Tian

Tu, Zhengliang
License Information

Text and Data Mining valid from 2024-06-10

Version of Record valid from 2024-06-10
More Information

Article History

Received: 18 July 2023

Accepted: 30 May 2024

First Online: 10 June 2024

Declarations

:

: The study protocol was approved by the ethics committee of the First Affiliated Hospital, Zhejiang University School of Medicine (reference number 2020-IIT-566) and conducted in following the Declaration of Helsinki and the International Council for Harmonization Guidelines for Good Clinical Practice. Written informed consent was obtained from all participants.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below